Onychomycosis Market Expected To Grow Steadily And Reach Nearly $5.08 Billion By 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Onychomycosis Market In 2026 And 2030?

The onychomycosis market has demonstrated substantial growth over recent years. It is forecast to expand from $3.81 billion in 2025 to $4.03 billion in 2026, driven by a compound annual growth rate (CAGR) of 5.7%. This historical progression can be linked to the high prevalence of onychomycosis, the constrained availability of sophisticated antifungal medications, an escalation in fungal nail infections associated with an aging population, enhanced awareness among dermatologists, and the early adoption of topical treatments.

The onychomycosis market size is projected to experience robust expansion in the coming years, reaching $5.09 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.0%. This anticipated growth during the forecast period is driven by factors such as an increasing demand for combined treatment approaches, greater integration of teledermatology and remote patient surveillance, the advancement of AI-supported diagnostic tools, broader distribution through hospitals and retail pharmacies, and heightened investment in research targeting resistant fungal strains. Key developments expected during this period involve the rising acceptance of customized antifungal treatments, wider application of teledermatology for diagnostic and monitoring purposes, the expanding deployment of AI-powered diagnostic solutions for nail infections, a heightened understanding of nail health and proper hygiene, and the continued development of combined drug and topical treatments.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12197&type=smp

What Key Factors Are Shaping The Onychomycosis Market Landscape?

The increasing number of individuals with diabetes is anticipated to fuel the expansion of the onychomycosis market in the future. Diabetes, a long-term condition, results from the pancreas producing insufficient insulin or the body not effectively using the insulin it produces. For individuals suffering from diabetes, onychomycosis is a frequent foot ailment, and its progression can be controlled through proactive prevention and careful management of related issues. Consequently, the growing occurrence of diabetes enhances the demand within the onychomycosis market. As an illustration, in June 2024, data from the National Health Service, a UK-based government entity, indicated that during 2023, the NHS identified more than 549,000 new individuals in England facing a risk of developing type 2 diabetes, thereby raising the total count of those with non-diabetic hyperglycemia, or pre-diabetes, recorded by a GP, to 3,615,330. This figure marks a substantial rise when contrasted with 3,065,825 in 2022, showing an increase of nearly 20%. Thus, the increasing prevalence of diabetes is a key factor propelling the expansion of the onychomycosis market.

Which Segments Define The Onychomycosis Market Segment Structure?

The onychomycosis market covered in this report is segmented –

1) By Type: Distal Subungual Onychomycosis (DSO), White Superficial Onychomycosis (WSO), Proximal Subungual Onychomycosis (PSO), Candida Onychomycosis, Other Types

2) By Treatment: Drug Treatment, Topical Therapy, Other Treatments

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Distal Subungual Onychomycosis (DSO): Dermatophyte Infections, Mixed Infections

2) By White Superficial Onychomycosis (WSO): Trichophyton Mentagrophytes Infections

3) By Proximal Subungual Onychomycosis (PSO): Associated with Nail Psoriasis, Fungal Infections In Immunocompromised Patients

4) By Candida Onychomycosis: Candidal Nail Infections, Mixed Fungal-Candida Infections

5) By Other Types: Total Nail Dystrophy, Secondary Onychomycosis

What Market Trends Are Affecting The Onychomycosis Market?

Leading companies in the onychomycosis market are developing innovative product formulations to maintain their market position. Such novel formulations contribute to the progression of the onychomycosis market by enhancing treatment outcomes and addressing particular challenges related to the condition. As an illustration, in February 2024, Moberg Pharma AB, a pharmaceutical company based in Sweden, launched MOB-015. This is a proprietary topical terbinafine formulation specifically designed to deliver effective concentrations directly to the nail and nail bed, thereby minimizing the systemic exposure risk associated with oral terbinafine. It has received recommendations for national approval in 13 European countries and is sold in Sweden under the brand name Terclara. This approval is supported by two Phase 3 trials, which revealed that MOB-015 achieved superior mycological cure rates (76% compared to up to 42% for comparators) and a significantly higher complete cure rate without any reported serious adverse reactions.

Who Are The Established Players Within The Onychomycosis Market?

Major companies operating in the onychomycosis market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sandoz International GmbH, Bausch Health Companies Inc., Perrigo Company plc, Galderma Laboratories LP, Aurobindo Pharma Limited, Cipla Inc., Dr.Reddy’s Laboratories Ltd., Apotex Inc, Lupin Limited, Amneal Pharmaceuticals Inc., Alembic Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Mayne Pharma Group Limited, Wockhardt Ltd., Jubilant Cadista Pharmaceuticals Inc., Moberg Pharma AB, Medimetriks Pharmaceuticals Inc., Blueberry Therapeutics Ltd., Hallux Inc., NovaBiotics Ltd., Zydus Cadila Healthcare Limited.

Get The Full Onychomycosis Market Report:

https://www.thebusinessresearchcompany.com/report/onychomycosis-global-market-report

Which Region Represents The Largest Share Of The Onychomycosis Market?

North America was the largest region in the onychomycosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onychomycosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Onychomycosis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/onychomycosis-global-market-report

Browse Through More Reports Similar to the Global Onychomycosis Market 2026, By The Business Research Company

Interactive Fitness Market Report 2026

https://www.thebusinessresearchcompany.com/report/interactive-fitness-global-market-report

Virtual Reality Vr Fitness Game Market Report

https://www.thebusinessresearchcompany.com/report/virtual-reality-vr-fitness-game-global-market-report

Fitness App Market Report

https://www.thebusinessresearchcompany.com/report/fitness-app-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795